Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine-producing hematopoietic cells

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2075-2080

  Kuçi, Zyrafete ^a   Seitz, Gabriele ^a   Kuçi, Selim ^a   Kreyenberg, Hermann ^a   Schumm, Michael ^a   Lang, Peter ^a   Niethammer, Dietrich ^a   Handgretinger, Rupert ^a   Bruchelt, Gernot ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Hematopoietic stem cells (CD34+ CD133+); Neuroblastoma; RT PCR; Tyrosine hydroxylase

Indexed keywords

CATECHOLAMINE; DOPAMINE BETA MONOOXYGENASE; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

APHERESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOPOIESIS; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

CATECHOLAMINES; CELL LINE, TUMOR; DOPAMINE BETA-HYDROXYLASE; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TYROSINE 3-MONOOXYGENASE;

EID: 33745634628     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pession A, Libri V, Sartini R, Conforti R, Margini E, Bernardi L, Fronza R, Olivetto E, Prete A, Tonelli R and Paolucci G: Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma. Oncol Rep 10: 357-362, 2003.
2. Lode HN, Handgretinger R, Schuermann U, Seitz G, Klingebiel T, Niethammer D and Beck J: Detection of neuroblastoma cells in CD34+ stem cells using a combination of tyrosine hydroxylase RT-PCR and anti-ganglioside GD2 immunohistochemistry. Eur J Cancer 33: 2024-2030, 1997.
3. Tsang KS, Li CK, Tsoi WC, Leung Y, Shing MM, Chik KW, Lee V, Ng MH and Yuen PM: Detection of micrometastases of neuroblasrtoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 97: 2887-2897, 2003.
4. Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P and Lewis IJ: Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Ped Oncol 36: 213-219, 2001.
5. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson ADJ, Pinkerton R and Selby P: Circulating neuroblastoma cells detected by reversed polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 15: 1795-1801, 2001.
6. Cheung IY and Cheung NK: Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Ped Oncol 36: 210-212, 2001.
7. Lambooy LHJ, Gidding CEM, van den Heuvel LP, Hulsbergenvan de Kaa CA, Ligtenberg M, Bökkerink JPM and De Abreu RA: Real time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection in neuroblastoma. Clin Cancer Res 9: 812-819, 2003.
8. Ito R, Asami S, Kagawa S, Motohashi S, Shicino H, Chin M, Yoshida Y, Nemoto N, Mugushima H and Suzuki T: Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biol Pharm Bull 27: 315-318, 2004.
9. Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A and Kagedal B: Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 49: 104-112, 2003.
10. Treuner J, Feine U, Niethammer D, Müller-Schauenberg W, Mainke J, Eichbach E, Dopfer R, Klingebiel T and Grumbach S: Scintigrafic imaging of neuroblastoma with iodobenzylguanidin. Lancet 1: 333-334, 1984.
11. Bergquist J, Tarkowski A, Ekman R and Ewing A: Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Nat Acad Sci USA 91: 12912-12916, 1994.
12. Musso NR, Brenci SB, Setti M, Indiveri F and Lotti G: Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J Clin Endocrinol Metabol 81: 3553-3557, 1996.
13. Reguzzoni M, Cosentino M, Rasini E, Marino F, Ferrari M, Bombelli R, Congiu T, Protasoni M, Quacci D, Lecchini S, Raspanti M and Frigo G: Ultrastructural localization of tyrosine hydroxylase in human PBMNC: effect of stimulation with phytohaemagglutinin. Cell Tiss Res 310: 297-304, 2002.
14. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A and Tayebati SK: Identification of dopamine-plasma membrane- and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 117: 133-142, 2001.
15. Cosentino M, Bombelli R and Ferrari M: HPLC-ED measurements of endogeneous catecholamines in human immune cells and hematopoietic cell lines. Life Sci 68: 283-295, 2000.
16. Freeman JG, Ryan JJ, Shelburne CP, Bailey DP, Bouton LA, Narasimhachari N, Domen J, Simeon N, Couderc F and Stewart JK: Catecholamines in bone marrow derived mast cells. J Neuroimmunol 119: 231-238, 2001.
17. Josefsson E, Bergquist J, Ekman R and Tarkowski A: Catecholamines are synthesised by mouse lymphocytes and regulate functions of these cells by induction of apoptosis. Immunology 88: 140-146, 1996.
18. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S and Frigo G: Endogenous catecholamine synthesis, metabolism, storage, and uptake in human peripheral blood mononuclear cells. Exp Hematol 27: 489-495, 1999.
19. + progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transpl 29: 731-736, 2002.
20. Marini P, MacLeod RAF, Treuner C, Bruchelt G, Böhm W, Wolburg H, Schweizer P and Girget R: SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic with high adrenergic differentiation. Cancer Genet Cytogenet 112: 161-164, 1999.
21. Rudolph G, Schilbach-Stückle K, Handgretinger R, Kaiser P and Hameister H: Cytogenetic and molecular characterization of newly-established neuroblastoma cell line LS. Hum Genet 86: 562-566, 1991.
22. Helson L, Helson C, Majeranowski A, Johnson G and Traganos F: Plasma DOPA, DOPA sulfate and neuroblastoma. In: Pediatric Oncology (Raybaud C and Clement R, eds.). Int. Congress series 570, Experta Medica, Amsterdam, Oxford, Princeton, pp. 110-114, 1982.
23. Parareda A, Villaescusa JC, Sanchez de Toledo J and Gallego S: New splicing variants for human tyrosine hydroxylase gene with possible implications for the detection of minimal residual disease in patients with neuroblastoma. Neurosci Lett 336: 29-32, 2003.
24. Kushner BH, Gulati SC, Kwon JH, O'Reilly RJ, Exelby PR and Cheung NK: High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 68: 242-247, 1991.
25. Kuçi Z, Bruchelt G, Seitz G, Karov Y, Or R, Handgretinger R, Niethammer D and Hahn T: Bone marrow derived factors support growth of N-type, but not of melanocytic neuroblastoma cells. Anticancer Res 22: 4325-4330, 2002.
26. Ifversen MR, Kagedal B, Christensen LD, Rechnitzer C, Petersen BL and Heilmann C: Comparison of immunocytochemistry, real-time RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 27: 121-129, 2005.
27. Burchill SA, Corrias MV, Kagedal B, Oltra S, Sletten M, Swerts K, Vicha A, Bennaceur A and Ladenstein R: Quality assurance of reverse transcriptase polymerase chain reaction (RT-PCR) to detect neuroblastoma: ESIOP Neuroblastoma Group. In: Advances in Neuroblastoma Research, Abstract booklet, pp. 86 (XI Conference, Genova, Italy, June 16-19, 2004).
28. Beiske K, Ambros PF, Burchill SA, Cheung IY and Swerts K: Detection minimal residual disease in neuroblastoma patients - the present state of the art. Cancer Lett 228: 229-240, 2005.
29. Handgretinger R, Leung W, Ihm K, Lang P, Klingebiel T and Niethammer D: Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer 88: 1874-1877, 2003.